Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021-June 2022
Description
To describe humoral immune responses to symptomatic SARS-CoV-2 infection, we assessed immunoglobulin G binding antibody levels using a commercial multiplex bead assay against SARS-CoV-2 ancestral spike protein receptor binding domain (RBD) and